KR102422800B1 - Composition for improvement of diabetes using silkworm and manufacturing method of the same - Google Patents
Composition for improvement of diabetes using silkworm and manufacturing method of the same Download PDFInfo
- Publication number
- KR102422800B1 KR102422800B1 KR1020200181261A KR20200181261A KR102422800B1 KR 102422800 B1 KR102422800 B1 KR 102422800B1 KR 1020200181261 A KR1020200181261 A KR 1020200181261A KR 20200181261 A KR20200181261 A KR 20200181261A KR 102422800 B1 KR102422800 B1 KR 102422800B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- silkworm
- diabetes
- present
- weight ratio
- Prior art date
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 77
- 230000006872 improvement Effects 0.000 title abstract description 15
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 42
- 244000061456 Solanum tuberosum Species 0.000 claims description 42
- 235000015277 pork Nutrition 0.000 claims description 30
- 244000163122 Curcuma domestica Species 0.000 claims description 23
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 23
- 235000003373 curcuma longa Nutrition 0.000 claims description 23
- 235000013976 turmeric Nutrition 0.000 claims description 23
- 235000012015 potatoes Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000004615 ingredient Substances 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 238000010171 animal model Methods 0.000 description 22
- 244000302512 Momordica charantia Species 0.000 description 21
- 235000009811 Momordica charantia Nutrition 0.000 description 21
- 238000005259 measurement Methods 0.000 description 19
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 15
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 15
- 229960001052 streptozocin Drugs 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 229940109239 creatinine Drugs 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 235000008708 Morus alba Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- 235000005273 Canna coccinea Nutrition 0.000 description 1
- 240000008555 Canna flaccida Species 0.000 description 1
- 235000015844 Citrullus colocynthis Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000610628 Trichoptilium incisum Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- YKNYRRVISWJDSR-UHFFFAOYSA-N methyl oxirane-2-carboxylate Chemical compound COC(=O)C1CO1 YKNYRRVISWJDSR-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Insects & Arthropods (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 누에를 이용한 당뇨 개선을 위한 조성물 및 이의 제조 방법에 관한 것으로서, 더욱 상세히는 당뇨에 효능이 있는 누에와 다른 재료들을 혼합하여 누에가 가진 당뇨 관련 효능과 큰 차이가 없는 조성물을 제공하는 누에를 이용한 당뇨 개선을 위한 조성물 및 이의 제조 방법에 관한 것이다. 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 따라 제조된 누에를 이용한 당뇨 개선을 위한 조성물은 누에만을 재료로 하는 조성물과 당뇨 개선 효능에 있어서 큰 차이 없이 당뇨 개선 효능을 제공하는 효과가 있다.The present invention relates to a composition for improving diabetes using silkworm and a manufacturing method thereof, and more particularly, to a silkworm providing a composition that does not differ significantly from the diabetes-related efficacy of silkworms by mixing silkworms effective for diabetes with other ingredients It relates to a composition for improving diabetes using and a method for preparing the same. The composition for improving diabetes using silkworm prepared according to the method for preparing a composition for improving diabetes using silkworm according to an embodiment of the present invention exhibits diabetes improvement efficacy without a significant difference between a composition using silkworm only and diabetes improvement efficacy. has the effect of providing.
Description
본 발명은 누에를 이용한 당뇨 개선을 위한 조성물 및 이의 제조 방법에 관한 것으로서, 더욱 상세히는 당뇨에 효능이 있는 누에와 다른 재료들을 혼합하여 누에가 가진 당뇨 관련 효능과 큰 차이가 없는 조성물을 제공하는 누에를 이용한 당뇨 개선을 위한 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a composition for improving diabetes using silkworm and a manufacturing method thereof, and more particularly, to a silkworm providing a composition that does not differ significantly from the diabetes-related efficacy of silkworms by mixing silkworms effective for diabetes with other ingredients It relates to a composition for improving diabetes using and a method for preparing the same.
당뇨병은 인슐린의 절대적 또는 상대적 결핍이나 인슐린 기능 저하에 기인한 탄수화물, 지방 및 단백질 대사의 장애를 특징으로 하는 내분비계 질환으로 제1형인 인슐린 의존형과 제2형인 인슐린 비의존형으로 분류한다.Diabetes mellitus is an endocrine disease characterized by disturbances in carbohydrate, fat and protein metabolism due to absolute or relative deficiency of insulin or decreased insulin function.
당뇨병의 대부분을 차지하는 제2형 당뇨병의 인슐린(insulin)의 분비는 유전적, 비만, 고혈압 등과 관련이 높은 것으로 알려졌으며, 심혈관 질환의 발생비율이 비환자에 비해 2배 이상 높은 것으로 보고되고 있다.The secretion of insulin in
당뇨병의 공통된 특징으로 혈중의 높은 콜레스테롤과 중성지질이 높은 고지혈증을 수반하는 합병증으로서 이것은 심혈관기계 질환 발생과 밀접한 관계가 있는 것으로 알려졌다. 이에 따라 최근에 혈당을 정상화시켜 합병증 등을 개선하고 완화시키기 위한 생리활성을 갖는 기능성 식품소재의 연구가 이루어지고 있다.A common characteristic of diabetes is high cholesterol and high triglycerides in the blood, which is a complication accompanied by hyperlipidemia, which is known to be closely related to the occurrence of cardiovascular diseases. Accordingly, recently, research on functional food materials having physiological activity to normalize blood sugar to improve and alleviate complications and the like has been conducted.
이러한 식품소재 연구의 일례로 당뇨에 효능이 있는 것으로 알려진 누에를 이용하여 각종 식품의 재료로 이용하는데 대한 연구가 활발히 진행되고 있다.As an example of such food material research, research on using silkworms known to be effective in diabetes as a material for various foods is being actively conducted.
그러나, 누에의 가격이 상당하여 누에만으로 이루어진 식품에 대한 사용자의 비용 부담이 상당한 문제가 있다.However, since the price of silkworms is considerable, there is a significant problem in that the user's cost burden for food made of only silkworms is significant.
본 발명은 누에를 다른 재료와 혼합하여 생성한 조성물을 제공하여 누에가 가진 당뇨 개선 효능에 근접한 효능을 상기 조성물을 통해 제공할 수 있도록 하는데 그 목적이 있다.An object of the present invention is to provide a composition produced by mixing silkworm with other materials to provide an effect close to the diabetes improvement effect of silkworm through the composition.
또한, 본 발명은 누에를 다른 재료와 혼합하여 조성한 당뇨 개선을 위한 조성물을 제공함으로써, 누에만으로 이루어진 식품보다 가격 경쟁력을 갖추도록 지원할 수 있을 뿐 아니라 사용자의 비용 부담을 경감시킬 수 있도록 지원하는데 그 목적이 있다.In addition, the present invention provides a composition for improving diabetes prepared by mixing silkworms with other materials, thereby supporting not only to have price competitiveness compared to food made from only silkworms, but also to help reduce the user's cost burden. There is this.
본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법은 누에와 돼지감자 및 여주를 준비하는 단계 및 상기 누에와 돼지감자 및 여주를 미리 설정된 비율로 혼합하여 조성물을 제조하는 단계를 포함할 수 있다.The method for preparing a composition for improving diabetes using silkworm according to an embodiment of the present invention comprises the steps of preparing silkworm, pork potato and bitter melon, and mixing the silkworm, pork potato, and bitter melon in a preset ratio to prepare a composition may include
본 발명과 관련된 일 예로서, 상기 조성물은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 여주 0.5 중량비율 ~ 1.5 중량비율로 조성되는 것을 특징으로 할 수 있다.As an example related to the present invention, the composition may be characterized in that it is composed of the silkworm 1.5 weight ratio to 2.5 weight ratio, the pork potato 0.5 weight ratio to 1.5 weight ratio, and the bitter gourd 0.5 weight ratio to 1.5 weight ratio. .
본 발명의 다른 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법은 누에와 돼지감자 및 울금을 준비하는 단계 및 상기 누에와 돼지감자 및 울금을 미리 설정된 비율로 혼합하여 조성물을 제조하는 단계를 포함할 수 있다.The method for preparing a composition for improving diabetes using silkworm according to another embodiment of the present invention comprises the steps of preparing silkworm, pork potato and turmeric and mixing the silkworm, pork potato and turmeric in a preset ratio to prepare a composition may include.
본 발명과 관련된 일 예로서, 상기 조성물은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 울금 0.5 중량비율 ~ 1.5 중량비율로 조성되는 것을 특징으로 할 수 있다.As an example related to the present invention, the composition may be characterized in that it is composed of the silkworm 1.5 weight ratio to 2.5 weight ratio, the pork potato 0.5 weight ratio to 1.5 weight ratio, and the turmeric 0.5 weight ratio to 1.5 weight ratio. .
본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물은 누에와 돼지감자 및 여주가 2:1:1의 비율로 혼합되어 조성되는 조성물을 포함할 수 있다.The composition for improving diabetes using silkworms according to an embodiment of the present invention may include a composition in which silkworms, pork potatoes, and bitter gourd are mixed in a ratio of 2:1:1.
본 발명의 다른 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물은 누에와 돼지감자 및 울금이 2:1:1의 비율로 혼합되어 조성되는 조성물을 포함할 수 있다.The composition for improving diabetes using silkworms according to another embodiment of the present invention may include a composition in which silkworms, pork potatoes, and turmeric are mixed in a ratio of 2:1:1.
본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 따라 제조된 누에를 이용한 당뇨 개선을 위한 조성물은 누에만을 재료로 하는 조성물과 당뇨 개선 효능에 있어서 큰 차이 없이 당뇨 개선 효능을 제공하는 효과가 있다.The composition for improving diabetes using silkworm prepared according to the method for preparing a composition for improving diabetes using silkworm according to an embodiment of the present invention exhibits diabetes improvement efficacy without a significant difference between a composition using silkworm only and diabetes improvement efficacy. has the effect of providing.
또한, 본 발명은 누에에 돼지감자 및 여주 또는 돼지감자 및 울금을 혼합하여 조성물을 제조함으로써, 누에만으로 이루어져 가격이 비싼 식품보다 가격 경쟁력을 갖춤과 아울러 누에만으로 이루어진 식품과 당뇨 개선 효능에 있어서 큰 차이가 없는 본 발명의 조성물로 이루어진 식품을 제공할 수 있으며 이를 통해 사용자의 비용 부담을 경감시킬 수 있는 효과가 있다.In addition, the present invention prepares a composition by mixing silkworm with pig potato and bitter gourd or pork potato and turmeric, so that it has price competitiveness compared to expensive food made of only silkworm, and there is a big difference in the efficacy of improving diabetes with food made of only silkworm It is possible to provide a food made of the composition of the present invention without there is an effect that can reduce the user's cost burden through this.
도 1은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 대한 순서도.
도 2는 본 발명의 다른 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 대한 순서도.
도 3 및 도 4는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 따라 제조된 조성물의 샘플에 대한 a-glucosidase 활성을 측정하여 다른 조성물과의 비교 결과를 나타낸 도면.
도 5는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 체중 측정 결과를 나타낸 도면.
도 6은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 간 무게 측정 결과를 나타낸 도면.
도 7은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 혈당 측정 결과를 나타낸 도면.
도 8은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 총 콜레스트롤(Total Cholesterol) 측정 결과를 나타낸 도면.
도 9는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 트리글리세리드(Triglyceride) 측정 결과를 나타낸 도면.
도 10은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 LDL-Cholesterol 측정 결과를 나타낸 도면.
도 11은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 크레아티닌(Creatinine) 측정 결과를 나타낸 도면.1 is a flowchart of a method for preparing a composition for improving diabetes using silkworms according to an embodiment of the present invention.
Figure 2 is a flow chart for a method for preparing a composition for improving diabetes using silkworms according to another embodiment of the present invention.
3 and 4 are views showing comparison results with other compositions by measuring a-glucosidase activity for a sample of a composition prepared according to the method for preparing a composition for improving diabetes using silkworm according to an embodiment of the present invention.
5 is a view showing the weight measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
6 is a view showing the liver weight measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
7 is a view showing the blood glucose measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
8 is a view showing the measurement results of total cholesterol (Total Cholesterol) according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
9 is a view showing the measurement results of triglyceride (Triglyceride) according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
10 is a view showing the LDL-Cholesterol measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
11 is a view showing the measurement results of creatinine (Creatinine) according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
본 발명에서 사용되는 기술적 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아님을 유의해야 한다. 또한, 본 발명에서 사용되는 기술적 용어는 본 발명에서 특별히 다른 의미로 정의되지 않는 한, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 의미로 해석되어야 하며, 과도하게 포괄적인 의미로 해석되거나, 과도하게 축소된 의미로 해석되지 않아야 한다. 또한, 본 발명에서 사용되는 기술적인 용어가 본 발명의 사상을 정확하게 표현하지 못하는 잘못된 기술적 용어일 때에는 당업자가 올바르게 이해할 수 있는 기술적 용어로 대체되어 이해되어야 할 것이다. 또한, 본 발명에서 사용되는 일반적인 용어는 사전에 정의되어 있는 바에 따라, 또는 전후 문맥상에 따라 해석되어야 하며, 과도하게 축소된 의미로 해석되지 않아야 한다.It should be noted that the technical terms used in the present invention are only used to describe specific embodiments, and are not intended to limit the present invention. In addition, the technical terms used in the present invention should be interpreted as meanings generally understood by those of ordinary skill in the art to which the present invention belongs, unless otherwise defined in the present invention, and excessively comprehensive It should not be construed as a human meaning or in an excessively reduced meaning. In addition, when the technical term used in the present invention is an incorrect technical term that does not accurately express the spirit of the present invention, it should be understood by being replaced with a technical term that can be correctly understood by those skilled in the art. In addition, general terms used in the present invention should be interpreted as defined in advance or according to the context before and after, and should not be interpreted in an excessively reduced meaning.
또한, 본 발명에서 사용되는 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한 복수의 표현을 포함한다. 본 발명에서 "구성된다" 또는 "포함한다" 등의 용어는 발명에 기재된 여러 구성 요소들 또는 여러 단계를 반드시 모두 포함하는 것으로 해석되지 않아야 하며, 그 중 일부 구성 요소들 또는 일부 단계들은 포함되지 않을 수도 있고, 또는 추가적인 구성 요소 또는 단계들을 더 포함할 수 있는 것으로 해석되어야 한다.Also, the singular expression used in the present invention includes the plural expression unless the context clearly dictates otherwise. In the present invention, terms such as "consisting of" or "comprising" should not be construed as necessarily including all of the various components or various steps described in the invention, and some components or some steps may not be included. It should be construed that it may further include additional components or steps.
또한, 본 발명에서 사용되는 제 1, 제 2 등과 같이 서수를 포함하는 용어는 구성 요소들을 설명하는데 사용될 수 있지만, 구성 요소들은 용어들에 의해 한정되어서는 안 된다. 용어들은 하나의 구성 요소를 다른 구성 요소로부터 구별하는 목적으로만 사용된다. 예를 들어, 본 발명의 권리 범위를 벗어나지 않으면서 제 1 구성 요소는 제 2 구성 요소로 명명될 수 있고, 유사하게 제 2 구성 요소도 제 1 구성 요소로 명명될 수 있다.Also, terms including ordinal numbers such as first, second, etc. used in the present invention may be used to describe the components, but the components should not be limited by the terms. The terms are used only for the purpose of distinguishing one component from another. For example, without departing from the scope of the present invention, a first component may be referred to as a second component, and similarly, the second component may also be referred to as a first component.
이하, 첨부된 도면을 참조하여 본 발명에 따른 바람직한 실시예를 상세히 설명하되, 도면 부호에 관계없이 동일하거나 유사한 구성 요소는 동일한 참조 번호를 부여하고 이에 대한 중복되는 설명은 생략하기로 한다.Hereinafter, a preferred embodiment according to the present invention will be described in detail with reference to the accompanying drawings, but the same or similar components are given the same reference numerals regardless of the reference numerals, and the redundant description thereof will be omitted.
또한, 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다. 또한, 첨부된 도면은 본 발명의 사상을 쉽게 이해할 수 있도록 하기 위한 것일 뿐, 첨부된 도면에 의해 본 발명의 사상이 제한되는 것으로 해석되어서는 아니 됨을 유의해야 한다.In addition, in the description of the present invention, if it is determined that a detailed description of a related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted. In addition, it should be noted that the accompanying drawings are only for easy understanding of the spirit of the present invention, and should not be construed as limiting the spirit of the present invention by the accompanying drawings.
이하에서는, 본 발명에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법을 도면을 참고하여 상세히 설명한다.Hereinafter, a method for preparing a composition for improving diabetes using silkworm according to the present invention will be described in detail with reference to the drawings.
도 1은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 대한 순서도이다.1 is a flowchart of a method for preparing a composition for improving diabetes using silkworms according to an embodiment of the present invention.
도시된 바와 같이, 누에와 돼지감자 및 여주를 준비한다(S1).As shown, prepare silkworm, pork potato and bitter gourd (S1).
다음, 누에와 돼지감자 및 여주를 미리 설정된 비율로 혼합하여 조성물을 제조한다(S2).Next, a composition is prepared by mixing silkworm, pork potato, and bitter melon in a preset ratio (S2).
이때, 상기 미리 설정된 비율은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 여주 0.5 중량비율 ~ 1.5 중량비율일 수 있다.In this case, the preset ratio may be the silkworm 1.5 weight ratio to 2.5 weight ratio, the pork potato 0.5 weight ratio to 1.5 weight ratio, and the bitter gourd 0.5 weight ratio to 1.5 weight ratio.
이에 따라, 상기 누에와 돼지감자 및 여주를 혼합하여 조성된 조성물은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 여주 0.5 중량비율 ~ 1.5 중량비율로 조성될 수 있다.Accordingly, the composition prepared by mixing the silkworm, pork potato and bitter gourd is the silkworm 1.5 weight ratio to 2.5 weight ratio, the pig potato 0.5 weight ratio to 1.5 weight ratio, and the bitter gourd 0.5 weight ratio to 1.5 weight ratio. can
바람직하게는, 상기 누에와 돼지감자 및 여주를 혼합하여 조성된 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물은 누에와 돼지감자 및 여주가 2:1:1의 비율로 혼합되어 조성되는 것이 바람직하다.Preferably, the composition for improving diabetes using a silkworm according to an embodiment of the present invention, which is prepared by mixing the silkworm, pig potato, and bitter melon, is a composition in which silkworm, pork potato, and bitter melon are mixed in a ratio of 2:1:1 It is preferable to be
도 2는 본 발명의 다른 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 대한 순서도이다.2 is a flowchart of a method for preparing a composition for improving diabetes using silkworms according to another embodiment of the present invention.
도시된 바와 같이, 누에와 돼지감자 및 울금을 준비한다(S11).As shown, prepare silkworm, pork potato and turmeric (S11).
다음, 누에와 돼지감자 및 울금을 미리 설정된 비율로 혼합하여 조성물을 제조한다(S12).Next, a composition is prepared by mixing silkworm, pork potato and turmeric in a preset ratio (S12).
이때, 상기 미리 설정된 비율은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 울금 0.5 중량비율 ~ 1.5 중량비율일 수 있다.At this time, the preset ratio may be the silkworm 1.5 weight ratio ~ 2.5 weight ratio, the pork potato 0.5 weight ratio ~ 1.5 weight ratio, the turmeric 0.5 weight ratio ~ 1.5 weight ratio.
이에 따라, 상기 누에와 돼지감자 및 울금을 혼합하여 조성된 조성물은 상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 울금 0.5 중량비율 ~ 1.5 중량비율로 조성될 수 있다.Accordingly, the composition prepared by mixing the silkworm with the pig potato and turmeric is the silkworm 1.5 weight ratio to 2.5 weight ratio, the pig potato 0.5 weight ratio to 1.5 weight ratio, and the turmeric 0.5 weight ratio to 1.5 weight ratio. can
바람직하게는 상기 누에와 돼지감자 및 울금을 혼합하여 조성된 본 발명의 다른 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물은 누에와 돼지감자 및 울금이 2:1:1의 비율로 혼합되어 조성되는 것이 바람직하다.Preferably, the composition for improving diabetes using a silkworm according to another embodiment of the present invention, which is prepared by mixing the silkworm, pig potato, and turmeric, is a composition in which silkworm, pig potato, and turmeric are mixed in a ratio of 2:1:1 It is preferable to be
상기 누에는 나비목 누에나방과에 속하는 누에나방의 유충으로서, 누에의 혈당강하의 기전은 1-Deoxynojirimycin(DNJ) 라는 α-glucosidase 저해제의 기능에서 비롯한다. DNJ는 뽕나무와 누에에 포함된 수용성 알칼로이드 가운데 가장 높은 비율로 존재하며，DNJ 함량은 뽕나무와 누에로 만든 건강기능식품의 혈당강하효능의 지표로 여겨지고 있다.The silkworm is a larva of the silkworm moth belonging to the Lepidoptera family Lepidoptera, and the mechanism of lowering blood sugar in silkworms is derived from the function of an α-glucosidase inhibitor called 1-Deoxynojirimycin (DNJ). DNJ exists in the highest ratio among water-soluble alkaloids contained in mulberry and silkworm, and the DNJ content is considered as an indicator of the blood sugar-lowering effect of health functional foods made from mulberry and silkworm.
누에에 함유되어 있는 DNJ성분은 뽕잎 중의 DNJ 농도의 2~3배로 존재 하는 것이 관찰되어 뽕잎 중의 DNJ가 누에 안에서 축적이 되는 것으로 생각된다. α-glucosidase 저해제는 소장의 융모막에서 이당류가 단당류로 분해되는 과정을 억제함으로써 장내에서 당질의 소화와 포도당의 흡수를 지연시켜 식후 혈당이 급격히 상승하여 인슐린이 과도하게 분비되는 것을 막아주게 된다.It was observed that the DNJ component contained in silkworms is present at 2-3 times the DNJ concentration in mulberry leaves, and it is thought that DNJ in mulberry leaves is accumulated in silkworms. α-glucosidase inhibitors inhibit the process of decomposition of disaccharides into monosaccharides in the chorion of the small intestine, thereby delaying the digestion of carbohydrates and absorption of glucose in the intestine.
또한, 상기 돼지감자는 높이 1.5~3m 정도로 곧게 자라며 겉에 거친 털이 있어 껄끄럽다. 잎은 아래쪽에서는 마주달리고 윗부분 에서는 어긋나게 달린다. 잎몸은 타원형으로 가장자리에 톱니가 있고 잎자루에 날개가 있다. 9~10월 줄기 끝에 많은 가지가 갈라져 지름 8cm 정도의 해바라기를 닮은 노란색의 두상화가 달린다. 설상화는 10개 이상이고 컵모양의 총포가 있으며 총포조각은 2~3줄로 배열한다. 열매는 수과로 겉에 돌기가 있다. 땅 속에 있는 덩이 모양의 뿌리줄기를 '돼지감자'라 하여 식용하거나 사료로 이용한다.In addition, the pork potato grows upright to about 1.5 to 3 m in height and has rough hairs on the surface and is gritty. The leaves are opposite at the bottom and opposite at the top. The petiole is oval in shape, with saw teeth on the edge and wings on the petiole. From September to October, many branches are split at the end of the stem, and a yellow head flower resembling a sunflower with a diameter of about 8cm hangs. There are more than 10 snowshoes and there are cup-shaped guns, and the gun pieces are arranged in 2-3 rows. The fruit is aqueous and has bumps on the outside. The tuberous rhizome in the ground is called 'pork potato' and is used as food or feed.
돼지감자에는 일반 감자의 약 75배의 이눌린(inulin)을 함유하고 있는데 이눌린은 천연 인슐린 역할을 해 혈당을 낮추는 데 도움을 주고 콜레스테롤 개선, 원활한 배변 활동, 식후 혈당 상승 억제에 좋다. 또한, 돼지감자는 탄수화물(15.1%), 단백질(1.9%)과 비타민C, 칼륨 등의 무기질을 함유하고 있으며, 철분도 풍부해 면역력 증진과 피로 해소에 좋다. 그뿐만 아니라, 돼지감자는 열량이 낮고 식이섬유가 풍부해 장 건강에 도움을 주며, 독소 배출을 원활하게 해 줘 다이어트에도 효과적인 식품이다.Pork potatoes contain about 75 times more inulin than ordinary potatoes. Inulin acts as a natural insulin to help lower blood sugar, improve cholesterol, smooth bowel movements, and suppress postprandial blood sugar rise. In addition, pork potato contains carbohydrates (15.1%), protein (1.9%) and minerals such as vitamin C and potassium, and is rich in iron, which is good for improving immunity and relieving fatigue. In addition, pork potatoes are low in calories and rich in dietary fiber, which helps to maintain intestinal health and facilitates the discharge of toxins, making it an effective food for diet.
또한, 여주는 1년생 덩굴성 박과 식물로 돌기가 촘촘하고 길쭉하여 도깨비방망이 같은 생김새를 가지고 있으며, 쓴맛이 강해 '쓴 오이'라고도 불린다. 중국이나 인도 등의 전통의학 자료에서는 여주를 중요한 약재로 이용한 기록들이 남아있으며, 세계적인 장수마을 중 하나인 일본의 오키나와 지방에서는 여주를 ‘고야’라고 하며, 건강식품 소재로 사용하고 있다. 여주는 혈당조절에 뛰어난 효능을 가지고 있으며, 면역력 강화, 장 기능 개선 등 다양한 기능성을 보유하고 있어 건강 식재료로 주목받고 있다. 최근에는 여주의 활용도가 다양해지면서 주산지인 경남 함양뿐만 아니라, 전남 해남, 신안, 경북 울진 등의 지역에서도 재배하고 있으며, 여주즙, 여주환 등 건강식품뿐만 아니라 여주장아찌, 여주가루 등 다양한 방법으로 상품화를 시도하고 있다.Also, Yeoju is an annual creeping gourd plant with dense and elongated projections that resembles a goblin bat, and is also called 'bitter cucumber' because of its strong bitter taste. There are records of using bitter gourd as an important medicinal material in traditional medicine materials such as China and India. Bitter gourd has an excellent effect on blood sugar control, and has various functions such as strengthening immunity and improving intestinal function, so it is attracting attention as a health food. Recently, as the utilization of Yeoju has been diversified, it is grown not only in Hamyang, South Gyeongsang Province, but also in Haenam, Sinan, and Uljin in North Gyeongsang Province. are trying
이러한, 여주에는 당뇨와 고혈압 등 성인병에 좋다고 알려진 카란틴(charantin)과 식물 인슐린이 풍부하다. 이때, 여주의 식물 인슐린은 P-인슐린 성분으로 포도당이 간에서 연소되도록 하며, 체내에서의 재합성을 억제하여 혈당이 축적되는 것을 방지한다. 카라틴 성분은 췌장의 베타세포를 활성화해 인슐린 분비를 촉신시킴으로써 혈당을 낮추는 효능이 있다. 이외에도 여주에는 항산화 작용을 하는 비타민 C(100g당 76mg 함유)가 레몬(70mg), 오렌지(43mg)보다 많이 함유되어 있다. 여주의 쓴맛을 내는 원인물질은 모모르데신이라는 성분으로 장 기능 개선, 혈중 콜레스테롤 수치 조절에 도움을 준다. Yeoju is rich in charantin and plant insulin, which are known to be good for adult diseases such as diabetes and high blood pressure. At this time, the plant insulin of bitter gourd is a P-insulin component that allows glucose to be burned in the liver and inhibits resynthesis in the body to prevent the accumulation of blood sugar. Caratin has the effect of lowering blood sugar by activating the beta cells of the pancreas and promoting insulin secretion. In addition, bitter gourd contains more vitamin C (containing 76 mg per 100 g), an antioxidant than lemon (70 mg) and orange (43 mg). The substance responsible for bitter taste of bitter gourd is momordesin, which helps improve intestinal function and control blood cholesterol levels.
또한, 울금은 카레의 주원료 이기도 하며 생강과의 여러해 살이풀에 속하는 다년초로서 고온다습한 곳에서 자생하는 식물이다. 울금의 생김새는 잎은 파초나 칸나처럼 긴 타원형이며 두줄기로 뻗어 다자란 높이가 1~1.5m가량이고 뿌리는 생강과 같으며 늦 여름에는 꽃이 핀다.Also, turmeric is the main raw material for curry, and it is a perennial plant belonging to the ginger family, and it is a plant that grows wild in hot and humid places. The appearance of turmeric leaves is long oval like green leaf or canna, stretched in two stems and grown to about 1-1.5m in height, the roots are like ginger, and flowers bloom in late summer.
이러한 울금은 커큐민(curcumin)을 주성분으로 하며, 커큐민은 활성 산소를 없애는 힘이 강해 강력한 항산화 작용을 하며, 혈당을 낮추고 혈전(혈관이 막히는 일)을 억제하는 작용을 하기 때문에 당뇨병을 예방하고 개선하는데도 도움을 준다.Such turmeric has curcumin as its main ingredient, and curcumin has a strong antioxidant effect due to its strong ability to remove free radicals. help
도 3 및 도 4는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 따라 제조된 조성물의 샘플에 대한 a-glucosidase 활성을 측정하여 다른 조성물과의 비교 결과를 나타낸 것이다.3 and 4 show comparison results with other compositions by measuring a-glucosidase activity for a sample of a composition prepared according to the method for preparing a composition for improving diabetes using silkworm according to an embodiment of the present invention.
도시된 바와 같이, 누에와 돼지감자 및 여주를 혼합하여 제조된 본 발명의 실시예에 따른 조성물에 대한 샘플 7번(GHW7)과, 누에와 돼지감자 및 울금을 혼합하여 제조된 본 발명의 실시예에 따른 조성물에 대한 샘플 8번(GHW8)에 대한 다른 재료들로부터 얻어진 다른 샘플들과의 a-glucosidase 활성을 측정한 결과를 비교해 보면, 샘플 7번 및 8번에서 낮은 활성을 나타내어 샘플 7번 및 8번의 재료들이 a-glucosidase 활성을 다른 재료에 비하여 억제시키는 경향으로 볼 수 있다.As shown, Sample No. 7 (GHW7) for a composition according to an embodiment of the present invention prepared by mixing silkworm, pork potato and bitter gourd, and an example of the present invention prepared by mixing silkworm, pork potato, and turmeric Comparing the results of measuring a-glucosidase activity with other samples obtained from other materials for sample 8 (GHW8) for the composition according to Materials No. 8 can be seen as a tendency to inhibit a-glucosidase activity compared to other materials.
이는 다당류가 단당류로 분해되는 과정에 관여하는 효소인 α-glucosidase에 경쟁적으로 결합하여 효소 활성을 억제함으로서 장내에서 당질의 소화와 흡수를 지연시켜 식후 급격한 혈당의 상승과 이에 따른 불필요한 인슐린의 분비를 억제해 주는 기전에 의한 것이다. 본 결과를 바탕으로 누에와 샘플 7번 및 8번의 동물실험을 진행하였다.It competitively binds to α-glucosidase, an enzyme involved in the process of decomposition of polysaccharides into monosaccharides, and inhibits enzyme activity, thereby delaying the digestion and absorption of carbohydrates in the intestine, thereby suppressing the rapid rise in blood glucose after meals and unnecessary secretion of insulin. It is by the mechanism that does it. Based on these results, animal experiments were conducted with silkworms and samples No. 7 and No. 8.
[실험예][Experimental example]
시험의뢰 기관으로부터 3종의 동결건조 상태의 샘플을 수령하였으며, 샘플 3종 각각으로부터 얻어진 시료는 냉동보관하고, 필요시 해동하여 적절한 시험농도로 증류수로 희석 후 시험에 사용하였다.Three types of samples in the lyophilized state were received from the test requesting institution, and samples obtained from each of the three types of samples were stored in a freezer, thawed if necessary, diluted with distilled water to an appropriate test concentration, and then used for testing.
샘플 3종의 시료는 샘플당 총 100g 무게로 칭량하여 3L의 증류수에 100℃에서 6시간 동안 냉각관을 통해 환류추출하고, 원심분리기에서 5000rpm, 15min 조건으로 원심분리하여 상등액을 취한 후, filter paper로 여과 후 동결건조 하였다. 샘플 3종에 대한 정보는 시험의뢰 기관에서 비공개로 진행하였다.Samples of three types of samples are weighed in a total weight of 100 g per sample, refluxed in 3 L of distilled water at 100 ° C. for 6 hours through a cooling tube, centrifuged in a centrifuge under 5000 rpm, 15 min conditions to take the supernatant, and filter paper It was filtered and then freeze-dried. Information on three types of samples was conducted privately by the test requesting institution.
이때, 하기 [표 1]에 도시된 바와 같이, 샘플 3종은 각각 샘플 1과 샘플 2 및 샘플 3으로 구성되고, 샘플 1(sample 1)은 누에만으로 구성된 조성물로부터 얻어진 샘플이고, 샘플 2(sample 2)는 본 발명의 실시예에 따른 누에와 돼지감자 및 울금을 2:1:1로 혼합하여 제조된 조성물로부터 얻어진 샘플이며, 샘플 3(sample 3)는 본 발명의 실시예에 따른 누에와 돼지감자 및 여주를 2:1:1로 혼합하여 제조된 조성물로부터 얻어진 샘플이다.At this time, as shown in [Table 1] below, the three types of samples consist of
또한, 상기 샘플 3 종에 대한 시험분석을 위해 사용된 시약은 하기 [표 2]와 같다.In addition, the reagents used for the test analysis of the three types of samples are shown in [Table 2] below.
실험동물은 7주령의 Sprague-Dawley계 수컷 흰쥐(SD rat, 200~220g)를 (주)오리엔트바이오(경기도, 한국)로부터 분양받아 1주간의 적응기간 동안 순화시킨 후 실험에 사용하였다. 실험기간동안 일반 고형사료(삼양사료주식회사, 서울, 한국)와 물을 자유 섭취시키며, 명암은 12시간(Day light 07:00 ~ 19:00)을 주기로, 실내온도는 23±2℃, 습도 50±10%로 유지하여 실험종료 시까지 일정한 사육조건을 유지시켰다.As experimental animals, 7-week-old male Sprague-Dawley rats (SD rats, 200-220g) were pre-distributed from Orient Bio (Gyeonggi-do, Korea), acclimatized for one week, and then used in the experiment. During the experiment period, general solid feed (Samyang Feed Co., Ltd., Seoul, Korea) and water were freely ingested, the light and dark was given 12 hours (Day light 07:00 ~ 19:00), and the indoor temperature was 23±2℃, and the humidity was 50. By maintaining ±10%, constant breeding conditions were maintained until the end of the experiment.
또한, STZ(Streptozotocin)을 10mM citrate buffer(pH 4.5)에 녹여 절식 후 50mg/kg 농도로 복강투여로 주사하여 실험동물에 당뇨를 유발시켰다. 상기 STZ 투여 후 꼬리정맥으로부터 취한 혈액의 혈당농도와 체중에 따라 샘플 및 STZ가 투여되지 않은 노멀(Normal)군을 제외하고 군 분류를 하였다.In addition, STZ (Streptozotocin) was dissolved in 10 mM citrate buffer (pH 4.5) and injected intraperitoneally at a concentration of 50 mg/kg after fasting to induce diabetes in experimental animals. According to the blood glucose concentration and body weight of the blood taken from the tail vein after STZ administration, the sample and the normal group to which STZ was not administered were excluded from group classification.
이하에서 도면을 참고하여 설명되는 STZ는 당뇨가 유발된 실험동물군을 의미하고, N은 노멀군을 의미하며, S1은 당뇨가 유발된 실험동물군에 상기 샘플 1의 시료를 투여한 실험동물군을 의미하고, S2는 당뇨가 유발된 실험동물군에 상기 샘플 2의 시료를 투여한 실험동물군을 의미하며, S3는 당뇨가 유발된 실험동물군에 상기 샘플 3의 시료를 투여한 실험동물군을 의미한다.STZ, which will be described below with reference to the drawings, means a group of diabetic-induced experimental animals, N means a normal group, and S1 is a group of experimental animals in which the sample of
-체중 측정- weight measurement
체중은 전 실험 기간을 통하여 일정한 시간에 매주 2-3일 간격으로 측정하였다.Body weight was measured at regular intervals of 2-3 days every week throughout the entire experimental period.
- Sample 투여- Sample administration
S1, S2 및 S3에 대응되는 시료를 200mg/kg로 증류수에 녹여 일정한 시간에 매일 경구투여 하였다.Samples corresponding to S1, S2 and S3 were dissolved in distilled water at 200 mg/kg and orally administered daily at a fixed time.
- 혈당 측정- Blood glucose measurement
혈당은 Glucose 측정 시약(Asan kit)을 이용하여 흰 쥐의 꼬리 체혈을 통해 혈액을 채취 하여 serum을 얻었다. 전 실험 기간 동안 총 3차례의 혈당 측정을 하였다.For blood glucose, serum was obtained by collecting blood from the tail blood of white rats using a glucose measuring reagent (Asan kit). A total of three blood glucose measurements were performed during the entire experimental period.
- 혈액마커 측정 - Blood marker measurement
2주 간의 경구 투여가 끝난 후 1.5% isoflurane으로 흡입 마취 시킨 쥐의 심장에서 직접 혈액을 채취하여 실온에서 응고시킨 다음 4℃, 3,000rpm으로 20분간 원심분리 하여 혈청을 분리한 후 사용하기 전까지 -70℃의 냉동고에 보관하였다. 혈청 glucose, total cholesterol, triglyceride, low density lipoprotein(LDL) cholesterol, creatinine 등의 생화학적 분석을 시행하였으며, 혈청 내 glucose, total cholesterol, triglyceride의 농도 측정은 표준 효소비색법에 의한 kit(Asan, Gyeonggi, Korea)를 사용하여 측정하였고, low density lipoprotein(LDL) cholesterol, creatinine의 검사는 연구용 검사를 실시하는 이원의료재단에 분석 의뢰하였다.After 2 weeks of oral administration, blood is directly collected from the heart of rats anesthetized by inhalation with 1.5% isoflurane, coagulated at room temperature, and then centrifuged at 4°C and 3,000 rpm for 20 minutes to separate serum and -70 until use. It was stored in a freezer at ℃. Biochemical analysis of serum glucose, total cholesterol, triglyceride, low density lipoprotein (LDL) cholesterol, creatinine, etc. was performed, and the concentration of glucose, total cholesterol, and triglyceride in serum was measured using a standard enzyme colorimetric kit (Asan, Gyeonggi, Korea). ), and the tests for low density lipoprotein (LDL) cholesterol and creatinine were requested for analysis by the Iwon Medical Foundation, which conducts research tests.
도 5는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 체중 측정 결과를 나타낸 것이다.5 shows the weight measurement results according to the application of the composition for improving diabetes using silkworms according to an embodiment of the present invention to an experimental animal.
실험기간 동안의 평균 체중에 시료투여가 미치는 영향은 도시된 바와 같으며, 평균 체중을 당뇨 유발군(STZ, S1, S2, S3)간에 비교하면 당뇨대조군(STZ)은 149.5 g인데 비해 S1군에서 167.6g 으로 체중감소개선에 효과가 있었다. S2군은 161g으로 S1군 보다는 체중 개선 효과가 적었지만 당뇨대조군(STZ)에 비해 체중증가 효과가 있었다. S3군은 167.4g 으로 S1 군과 비슷한 수준으로 개선 효과가 나타났다.The effect of sample administration on the average body weight during the experiment period is as shown in the figure. When the average body weight was compared between the diabetes-induced groups (STZ, S1, S2, S3), the diabetic control group (STZ) was 149.5 g, whereas the S1 group had 149.5 g. It was effective in weight loss improvement at 167.6g. The S2 group weighed 161 g, which had less weight improvement effect than the S1 group, but had a weight gain effect compared to the diabetic control group (STZ). The S3 group was 167.4g, and the improvement effect was similar to that of the S1 group.
도시된 바와 같이, 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물은 당뇨로 인해 발생하는 체중감소를 개선하는 효과가 있는 것으로 나타났다.As shown, the composition for improving diabetes using silkworms according to an embodiment of the present invention was found to have an effect of improving weight loss caused by diabetes.
도 6은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 간 무게 측정 결과를 나타낸 것이다.6 shows the liver weight measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
당뇨대조군(STZ)의 흰쥐에서는 인슐린의 분비감소로 인해 당대사의 불균형이 초래되고 면역기능이 저하되며, 이로 인하여 장기의 비대현상이 나타나는 것으로 알려져있다. 당뇨 유발 후 2주간의 실험기간 동안 흰쥐의 간의 중량을 측정하였다. 그 결과, 간 조직의 무게에 대한 시료 경구투여의 영향은 크게 나타나지 않았다.It is known that in the rats of the diabetic control group (STZ), an imbalance in glucose metabolism is caused due to a decrease in insulin secretion, and the immune function is lowered, which leads to an enlarged organ. The weight of the liver of rats was measured during the experiment period of 2 weeks after diabetes induction. As a result, the effect of oral administration of the sample on the weight of the liver tissue was not significant.
도 7은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 혈당 측정 결과를 나타낸 것이다.7 shows the blood glucose measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
첫 날 군 분류를 혈당에 따라 나누었고, 7 day, 14 day에 혈당 측정을 하였다. 7 day의 혈청 glucose 농도는 당뇨대조군(STZ) 434 mg/dL에 비해 S1, S2, S3 군은 324 mg/dL, 353 mg/dL, 329 mg/dL으로 혈당이 현저히 낮아졌고, 14 day에는 당뇨대조군(STZ) 434 mg/dL에 비해 S1군 323 mg/dL, S3군 344 mg/dL, S2군 377mg/dL 순으로 혈당저하 효과가 나타났다.On the first day, the group was divided according to blood sugar, and blood sugar was measured on the 7th and 14th days. The serum glucose concentration at 7 days was 324 mg/dL, 353 mg/dL, and 329 mg/dL in the S1, S2, and S3 groups, compared to 434 mg/dL in the diabetic control group (STZ). Compared to the control group (STZ) 434 mg/dL, the blood glucose lowering effect was shown in the order of 323 mg/dL in the S1 group, 344 mg/dL in the S3 group, and 377 mg/dL in the S2 group.
도 8은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 총 콜레스트롤(Total Cholesterol) 측정 결과를 나타낸 것이다.Figure 8 shows the results of total cholesterol (Total Cholesterol) measurement according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
혈청 내 총 콜레스테롤 함량을 측정한 결과 S1 군은 94.36 mg/dL으로 당뇨대조군(STZ) 108.40 mg/dL에 비해 총 콜레스테롤 개선 효과가 나타났고, S2, S3 군에서는 112.8 mg/dL, 105 mg/dL으로 S3 군에서 개선 효과가 나타났다.As a result of measuring the total cholesterol content in the serum, the S1 group was 94.36 mg/dL, which improved total cholesterol compared to 108.40 mg/dL in the diabetic control group (STZ), and 112.8 mg/dL and 105 mg/dL in the S2 and S3 groups. As a result, an improvement effect was shown in the S3 group.
도 9는 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 트리글리세리드(Triglyceride) 측정 결과를 나타낸 것이다.9 shows the measurement results of triglyceride according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
혈청 내 중성지방 함량을 측정한 결과 당뇨대조군(STZ) 189 mg/dL에 비해 S1군 143.1 mg/dL, S2군 144.1 mg/dL, S3군 149.1 mg/dL 순으로 중성지방 수치의 개선 효과가 나타났다.As a result of measuring the triglyceride content in the serum, compared to 189 mg/dL in the diabetic control group (STZ), 143.1 mg/dL in the S1 group, 144.1 mg/dL in the S2 group, and 149.1 mg/dL in the S3 group showed an improvement effect in the triglyceride level. .
도 10은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 LDL-Cholesterol 측정 결과를 나타낸 것이다.10 shows the LDL-Cholesterol measurement results according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
혈청 내의 LDL-Cholesterol 함량을 측정한 결과 당뇨대조군(STZ) 9.6 mg/dL에 비해 S1군 7.6 mg/dL, S3군 7.7 mg/dL, S2군 9 mg/dL 순으로 개선 효과가 나타났다.As a result of measuring the LDL-Cholesterol content in the serum, the improvement effect was shown in the order of 7.6 mg/dL in the S1 group, 7.7 mg/dL in the S3 group, and 9 mg/dL in the S2 group compared to 9.6 mg/dL in the diabetic control group (STZ).
도 11은 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 실험 동물 적용에 따른 크레아티닌(Creatinine) 측정 결과를 나타낸 것이다.11 shows the measurement results of creatinine according to the experimental animal application of the composition for improving diabetes using silkworms according to an embodiment of the present invention.
혈청 내의 creatinine 함량을 측정한 결과 당뇨대조군(STZ) 0.42 mg/dL에 비해 S1군 0.32 mg/dL, S3군 0.33 mg/dL S2군 0.36 mg/dL 순으로 수치가 낮아졌고, 시료군에서 노멀군 0.37 mg/dL보다 낮은 수치로 보아 개선 효과가 큰 것으로 나타났다.As a result of measuring the creatinine content in the serum, compared with 0.42 mg/dL in the diabetic control group (STZ), the S1 group 0.32 mg/dL, S3 group 0.33 mg/dL S2 group 0.36 mg/dL, and the S2 group 0.36 mg/dL were lower in the order of values. A value lower than 0.37 mg/dL showed a large improvement effect.
상술한 실험 결과와 같이, 체중 부분에서 당뇨 유발군에 비해 체중감소 개선 효과가 나타났고, 전반적인 혈청 내 지질 함량 측정 결과를 바탕으로 혈중 지질 함량 개선에 효과가 있고, 신장 기능의 지표가 되는 creatinine 수치가 노멀군 보다 낮은 수치가 나타난 것으로 보아 신장 기능 개선에도 효과가 높은 것으로 보여진다. 따라서 S1, S2, S3의 시료가 당뇨병 개선에 도움을 줄 수 있는 것으로 나타났다.As shown in the above experimental results, there was an improvement in weight loss compared to the diabetes-induced group in the body weight part, and it was effective in improving the blood lipid content based on the overall serum lipid content measurement result, and the creatinine level as an indicator of kidney function As the value was lower than that of the normal group, it was shown that the effect was high in improving renal function. Therefore, it was found that samples of S1, S2, and S3 can help improve diabetes.
상술한 바와 같이, 본 발명의 실시예에 따른 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법에 따라 제조된 누에를 이용한 당뇨 개선을 위한 조성물은 누에만을 재료로 하는 조성물과 당뇨 개선 효능에 있어서 큰 차이 없이 당뇨 개선 효능을 제공할 수 있다.As described above, the composition for improving diabetes using silkworms prepared according to the method for preparing a composition for improving diabetes using silkworms according to an embodiment of the present invention is a composition using only silkworms as a material and a significant difference in diabetes improvement efficacy It can provide the effect of improving diabetes without
또한, 본 발명은 누에에 돼지감자 및 여주 또는 돼지감자 및 울금을 혼합하여 조성물을 제조함으로써, 누에만으로 이루어져 가격이 비싼 식품보다 가격 경쟁력을 갖춤과 아울러 누에만으로 이루어진 식품과 당뇨 개선 효능에 있어서 큰 차이가 없는 본 발명의 조성물로 이루어진 식품을 제공할 수 있으며 이를 통해 사용자의 비용 부담을 경감시킬 수 있다.In addition, the present invention prepares a composition by mixing silkworm with pig potato and bitter gourd or pork potato and turmeric, so that it has price competitiveness compared to expensive food made of only silkworm, and there is a big difference in the effect of improving diabetes with food made of silkworm only It is possible to provide a food product made of the composition of the present invention without the present invention, thereby reducing the user's cost burden.
전술된 내용은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 수정 및 변형이 가능할 것이다. 따라서, 본 발명에 개시된 실시예들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다. 본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.Those of ordinary skill in the art to which the present invention pertains may modify and modify the above-described contents without departing from the essential characteristics of the present invention. Therefore, the embodiments disclosed in the present invention are not intended to limit the technical spirit of the present invention, but to illustrate, and the scope of the technical spirit of the present invention is not limited by these embodiments. The protection scope of the present invention should be interpreted by the following claims, and all technical ideas within the scope equivalent thereto should be construed as being included in the scope of the present invention.
Claims (2)
상기 누에 1.5 중량비율 ~ 2.5 중량비율, 상기 돼지감자 0.5 중량비율 ~ 1.5 중량비율, 상기 울금 0.5 중량비율 ~ 1.5 중량비율로 혼합하여 혼합물을 제조하는 단계; 및
상기 혼합물 100g 당 3L의 증류수에 100℃에서 6시간 동안 냉각관을 통해 환류추출하고, 원심분리기에서 5000rpm, 15분 조건으로 원심분리하여 상등액을 취한 후, 필터로 여과 후 동결건조하는 단계를 포함하되,
상기 혼합물은 상기 누에, 돼지감자 및 울금을 2:1:1의 비율로 혼합하여 제조되는 것을 특징으로 하는 누에를 이용한 당뇨 개선을 위한 조성물의 제조 방법.Preparing silkworms and pork potatoes and turmeric;
Preparing a mixture by mixing the silkworm 1.5 weight ratio to 2.5 weight ratio, the pork potato 0.5 weight ratio to 1.5 weight ratio, and the turmeric 0.5 weight ratio to 1.5 weight ratio; and
The mixture was extracted under reflux through a cooling tube at 100° C. for 6 hours in 3 L of distilled water per 100 g of the mixture, centrifuged in a centrifuge under 5000 rpm, 15 minutes conditions to take the supernatant, followed by filtration with a filter and freeze-drying. ,
The mixture is a method of producing a composition for improving diabetes using silkworm, characterized in that it is prepared by mixing the silkworm, pork potato and turmeric in a ratio of 2: 1 : 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200181261A KR102422800B1 (en) | 2018-12-05 | 2020-12-22 | Composition for improvement of diabetes using silkworm and manufacturing method of the same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180155209A KR20200068344A (en) | 2018-12-05 | 2018-12-05 | Composition for improvement of diabetes using silkworm and manufacturing method of the same |
| KR1020200181261A KR102422800B1 (en) | 2018-12-05 | 2020-12-22 | Composition for improvement of diabetes using silkworm and manufacturing method of the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180155209A Division KR20200068344A (en) | 2018-12-05 | 2018-12-05 | Composition for improvement of diabetes using silkworm and manufacturing method of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200145808A KR20200145808A (en) | 2020-12-30 |
| KR102422800B1 true KR102422800B1 (en) | 2022-07-19 |
Family
ID=82607249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200181261A KR102422800B1 (en) | 2018-12-05 | 2020-12-22 | Composition for improvement of diabetes using silkworm and manufacturing method of the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102422800B1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050111657A (en) | 2004-05-21 | 2005-11-28 | 주식회사 엠디바이오알파 | Anti-diabets treatment with angelica species extracts |
| KR100749944B1 (en) * | 2005-10-05 | 2007-08-21 | 한국식품연구원 | Saponin fraction for lowering blood glucose prepared from Momordica charantia Linn and pharmaceutical composition containing the same |
| KR20150095323A (en) * | 2014-02-13 | 2015-08-21 | 송상민 | The manufacturing method of a natural blood glucose control drink |
-
2020
- 2020-12-22 KR KR1020200181261A patent/KR102422800B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Korean J Clin Lab Sci., Vol. 47, No. 4, pp. 203-208 (2015) |
| 김은. 전남특화작물인 비파와 울금의 항당뇨 효과. 목포대학교 석사학위논문. 2008.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200145808A (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xue et al. | Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose, blood lipid and hemorheological properties in streptozotocin-induced diabetic rats | |
| Paiz et al. | Glucose-lowering effect of xoconostle (Opuntia joconostle A. Web., Cactaceae) in diabetic rats | |
| US20110027305A1 (en) | Composition Comprising an Extract of Herbal Combination Thereof for Preventing and Treating Diabetes Mellitus | |
| CN105995993A (en) | Food composition applicable to diabetic and preparation method thereof | |
| Luka et al. | Hypoglycaemic properties of aqueous extracts of Anacardium occidentale, Moringa oleifera, Vernonia amygdalina and Helianthus annuus: a comparative study on some biochemical parameters in diabetic rats | |
| KR101105591B1 (en) | Functional rice for blood sugar down and making method thereof | |
| KR101282055B1 (en) | Anti diabetic fermented food comprising fermented noni and method of manufacturing the same | |
| JP2008273856A (en) | Material containing starfish essence as active ingredient | |
| Seyed-Mostafa et al. | The effects of Persian shallot extract on the levels of some blood biochemical parameters in streptozotocin-induced diabetic rats | |
| KR101118451B1 (en) | Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent] | |
| KR102422800B1 (en) | Composition for improvement of diabetes using silkworm and manufacturing method of the same | |
| KR101359806B1 (en) | Helianthus tuberous. and Cudrania tricuspidata complex extracts for decreasing blood glucose level and health funtional food comprising the same | |
| KR101400368B1 (en) | A composition comprising boiled powder or extract of Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
| KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR20120124659A (en) | A breeding method of protaetia breviitarsis, protaetia breviitarsis using the same, extracts from the same, a pharmaceutical composition for prevention or treatment of liver disease and health functional foods comprising the same as an effective component | |
| KR101204415B1 (en) | Compositions for Preventing or Treating Obesity, Hyperlipidemia or Fatty Liver | |
| KR20200068344A (en) | Composition for improvement of diabetes using silkworm and manufacturing method of the same | |
| KR20100080672A (en) | Formulation for hypoglycemic effect comprising purple-fleshed potato | |
| JP2009137913A (en) | Lipid metabolism improver | |
| Nwankpa et al. | Investigation of ethanol stem bark extract of Treculia africana on the haematological parameters of albino wistar rats | |
| KR101305553B1 (en) | Anti diabetic fermented food comprising fermented green tea and method of manufacturing the same | |
| Anyakudo et al. | Beneficial Impacts of Solanum aethiopicum L. in Diabetes Control | |
| El-Sheikh | MANGIFERA INDICA LEAVES EXTRACT MODULATES SERUM LEPTIN, ASYMMETRIC DIMETHYLARGININE AND ENDOTHELIN-1 LEVELS IN EXPERIMENTAL DIABETES MELLITUS. | |
| Johri¹ et al. | Studies on hypoglycemic and hypocholesterolemic effects of mulberry leaves | |
| KR100484312B1 (en) | Beverage contain aralia continentalis kitagawa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |